Published in BJU Int on September 06, 2006
[Chemotherapy for prostate cancer]. Wien Klin Wochenschr (2008) 0.79
Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial. World J Urol (2013) 0.78
The relevance of the procedures related to the physiotherapy in the interventions in patients with prostate cancer: short review with practice approach. Int J Biomed Sci (2014) 0.75
Current Patterns of Management of Advanced Prostate Cancer in Routine Clinical Practice in Spain. Prostate Cancer (2015) 0.75
"We talk it over"--mixed-method study of interdisciplinary collaborations in private practice among urologists and oncologists in Germany. BMC Cancer (2014) 0.75
Quality assessment in prostate cancer centers certified by the German Cancer Society. World J Urol (2015) 0.75
[Therapy of castration-resistant prostate cancer]. Wien Klin Wochenschr (2012) 0.75
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (2010) 19.74
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (2008) 19.58
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet (2007) 15.92
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol (2009) 8.16
EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol (2013) 7.48
Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer (2010) 7.25
EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol (2010) 7.20
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol (2008) 5.27
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol (2009) 5.05
Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol (2010) 4.43
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol (2011) 4.01
Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol (2011) 3.96
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol (2013) 3.79
Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol (2013) 3.45
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med (2012) 3.44
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol (2013) 3.38
Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med (2012) 3.21
Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol (2013) 3.20
How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol (2004) 2.92
A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci U S A (2006) 2.89
Novel artificial neural network for early detection of prostate cancer. J Clin Oncol (2002) 2.88
Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol (2010) 2.80
Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J Clin Oncol (2007) 2.79
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol (2011) 2.75
Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis. Anesthesiology (2008) 2.75
Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol (2011) 2.68
Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int (2010) 2.59
Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res (2009) 2.54
Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol (2013) 2.52
Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol (2011) 2.50
PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res (2012) 2.43
Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res (2010) 2.42
Castration-resistant prostate cancer: AUA Guideline. J Urol (2013) 2.36
Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983. J Clin Oncol (2012) 2.36
Quality of care for older patients with cancer in the Veterans Health Administration versus the private sector: a cohort study. Ann Intern Med (2011) 2.34
A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol (2012) 2.31
Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol (2006) 2.29
A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. Lancet Oncol (2012) 2.24
New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol (2011) 2.21
PC3 is a cell line characteristic of prostatic small cell carcinoma. Prostate (2011) 2.13
Side-effects of treatments for locally advanced prostate cancer. BJU Int (2006) 2.03
Presence of teratoma in orchiectomy specimen increases the need for postchemotherapy RPLND. Urol Oncol (2009) 2.03
Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. J Clin Oncol (2012) 2.00
Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol (2006) 1.98
Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res (2004) 1.97
Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. J Clin Oncol (2011) 1.92
Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer. J Clin Oncol (2009) 1.91
Statins and prostate cancer risk: a case-control study. Am J Epidemiol (2005) 1.90
Laparoscopic and open partial nephrectomy: a matched-pair comparison of 200 patients. Eur Urol (2009) 1.85
Improved detection of prostate cancer using classification and regression tree analysis. J Clin Oncol (2005) 1.85
Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Eur Urol (2007) 1.82
ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. Eur Urol (2011) 1.80
SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol (2011) 1.77
Toxicities of targeted therapy and their management in kidney cancer. Eur Urol (2011) 1.76
Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol (2012) 1.76
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol (2007) 1.75
Prevalence, severity, and health correlates of lower urinary tract symptoms among older men: the MrOS study. Urology (2006) 1.75
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res (2007) 1.74
Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up. Am J Kidney Dis (2008) 1.71
Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res (2005) 1.68
Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol (2014) 1.67
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol (2012) 1.66
Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol (2011) 1.64
Do differences in clinical symptoms and referral patterns contribute to the gender gap in bladder cancer? BJU Int (2013) 1.64
Benign prostatic hyperplasia: counting the cost of its management. BJU Int (2010) 1.64
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol (2012) 1.64
The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. J Urol (2006) 1.63
Optimising repeat prostate biopsy decisions and procedures. BJU Int (2011) 1.62
Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. Eur Urol (2010) 1.60
Use of androgen deprivation therapy for metastatic prostate cancer in older men. BJU Int (2008) 1.59
Clinical significance of the positive surgical margin based upon location, grade, and stage. Urol Oncol (2010) 1.57
Heat shock proteins: their role in urological tumors. J Urol (2003) 1.56
Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology (2007) 1.56
Indicators for research performance evaluation: an overview. BJU Int (2012) 1.56
A catalyst for change: the European cancer Patient's Bill of Rights. Oncologist (2014) 1.55
Is there an association between lower urinary tract symptoms and cardiovascular risk in men? A cross sectional and longitudinal analysis. Urology (2011) 1.54
Bilateral testicular germ cell tumors in Turkey: increase in incidence in last decade and evaluation of risk factors in 30 patients. J Urol (2007) 1.53
A meta-analysis of trials of transurethral needle ablation for treating symptomatic benign prostatic hyperplasia. BJU Int (2004) 1.53
Microstaging of pT1 transitional cell carcinoma of the bladder. Does it really differentiate two populations with different prognoses? (pT1 subcategory). Urol Int (2002) 1.51
Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. Eur Urol (2012) 1.50
Individualization of the biopsy protocol according to the prostate gland volume for prostate cancer detection. J Urol (2005) 1.50
Prevalence and predictors of benign lesions in renal masses smaller than 7 cm presumed to be renal cell carcinoma. Clin Genitourin Cancer (2012) 1.49
Phase II study of transdermal estradiol in androgen-independent prostate carcinoma. Cancer (2005) 1.49
'Prostatic evasive anterior tumours': the role of magnetic resonance imaging. BJU Int (2009) 1.48